After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Abstract: Learning-based control has demonstrated great promise for handling complex tasks in various applications. However, ensuring system safety under uncertain dynamics remains a significant ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Artificial intelligence is reshaping how humans see themselves, raising urgent ethical questions about autonomy, agency, and the construction of digital identities. A new study by Bogdan-Andrei Lungu ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

user@machine:~/work/zfs/module_build git:(zfs-2.3.2) $ make GEN gitrev make all-recursive make[1]: Entering directory '/home/user/work/zfs/module_build' Making all in ...

A new preprint from Georgia Tech and Rochester Institute of Technology demonstrates just how quickly AI models can escalate from mildly stereotypical depictions to full-blown hate narratives targeting ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...